医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aileron Therapeutics to Highlight Stapled Peptide Pipeline at 2013 AsiaTIDES Meeting

2013年02月26日 PM10:55
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass.

Aileron Therapeutics, Inc. today announced the company will deliver two presentations on February 27, 2013 at the IBC’s 5th Annual 2013 AsiaTIDES meeting in Tokyo, Japan. Tomi K. Sawyer, Ph.D., chief scientific officer and senior vice president, discovery and innovative technologies, will give a featured presentation titled “Stapled Peptide Drugs: Transforming Nature’s α-Helix into Breakthrough Medicines,” and Hubert C. Chen, M.D., vice president, clinical development, endocrine and metabolic disease, will present a plenary lecture titled “Stapled Growth-Hormone-Releasing Hormone as a Promising Peptide Therapeutic.”

The data presented will highlight Aileron’s growing Stapled Peptide pipeline, and the company’s ability to capitalize on the unique pharmacokinetic (PK) properties of Stapled Peptides to reach both intracellular and extracellular targets. Dr. Sawyer will discuss the impact on intracellular targets through a review of Aileron’s lead oncology program, a dual MDM2/MDMX inhibitor for the treatment of p53-dependent cancers, partnered with Roche. Dr. Chen will demonstrate the applicability of the Stapled Peptide platform to extracellular targets by highlighting Aileron’s first development candidate, ALRN-5281, a long-acting growth-hormone-releasing hormone (GHRH) agonist.

Stapled Peptides are a new class of drugs with a unique set of properties that fully capitalize on 25 years of genetic research to attack drivers of complex diseases, including cancer, endocrine/metabolic disorders and inflammation. The Stapled Peptide platform locks peptides into their biologically active shape and imparts pharmaceutical stability within the body. Stapled Peptide drugs, like ALRN-5281, are derived from natural peptides and are designed to remain in a safe and effective therapeutic range longer than traditional peptide hormones. This new class of drugs represents a fundamental scientific breakthrough as they offer the most advanced way to replicate normal human physiology to treat human disease.

About ALRN-5281

ALRN-5281 is a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and HIV lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases. Relative to GH injections, GHRH therapy produces a more physiological response, thereby minimizing safety and tolerability issues associated with chronic, excess GH replacement. Clinical evaluation of ALRN-5281 is expected to begin in early 2013 and will mark the first-ever Stapled Peptide human clinical trial.

About Aileron Therapeutics

Aileron Therapeutics is creating one of the first new classes of drugs in 20 years. Our proprietary Stapled Peptide drugs uniquely capitalize on 25 years of genetic research to attack the key drivers of complex diseases such as cancer, metabolic and endocrine conditions and inflammation. By harnessing one of the most common, but elusive, structures in nature – the alpha helical peptide, we believe that we can dramatically improve the treatment of these diseases and positively impact the lives of millions of patients. For more information, please visit www.aileronrx.com.

CONTACT

Pure Communications, Inc.
Dan Budwick, 973-271-6085

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent